Metoprolol and bradycardia
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol and Bradycardia: Risk Factors and Clinical Considerations
Metoprolol-Induced Bradycardia: General Incidence and Comparison to Other Beta-Blockers
Metoprolol, a commonly used beta-blocker, is associated with an increased risk of bradycardia, especially in certain patient populations. Studies show that patients with heart failure and atrial fibrillation treated with metoprolol experience more frequent episodes of bradycardia compared to those treated with other beta-blockers like bucindolol or carvedilol. For example, metoprolol users had higher rates of both bradycardia and severe bradycardia, and were less likely to reach target doses due to these adverse events 14. After adjusting for patient characteristics, metoprolol was linked to a higher risk of emergent bradycardia than carvedilol, although the overall incidence remained low .
Sex Differences in Metoprolol-Related Bradycardia
There is a notable sex-based difference in the risk of bradycardia with metoprolol. Women, particularly those with higher plasma concentrations of metoprolol, have a significantly increased risk of developing bradycardia compared to men, even after accounting for other health factors . This suggests that women may require closer monitoring or dose adjustments when prescribed metoprolol.
Genetic and Drug-Drug Interaction Factors
Metoprolol is primarily metabolized by the CYP2D6 enzyme. Individuals with poor CYP2D6 metabolism, either due to genetic factors or drug interactions (such as with terbinafine), are at higher risk for bradycardia because of increased metoprolol concentrations in the blood 569. Poor metabolizers experience greater reductions in heart rate and are more likely to develop bradycardia compared to those with normal CYP2D6 activity 69. This highlights the importance of considering genetic testing or reviewing potential drug interactions when prescribing metoprolol.
Metoprolol in Acute Atrial Fibrillation: Comparison with Diltiazem
When used for acute atrial fibrillation with rapid ventricular rate, metoprolol and diltiazem have similar rates of bradycardia as an adverse event. Meta-analyses show no significant difference in the incidence of bradycardia between the two drugs, although metoprolol is associated with a lower overall risk of adverse events compared to diltiazem 810. However, the absolute risk of bradycardia with either medication remains low in this setting.
Clinical Scenarios: Prevention and Management
In specific clinical scenarios, such as shoulder arthroscopy under interscalene block, prophylactic use of metoprolol can actually reduce the incidence of sudden bradycardic events, suggesting a protective effect in certain reflex-mediated situations . However, in most other settings, bradycardia is a dose-limiting side effect that may require dose reduction or switching to another agent .
Conclusion
Metoprolol is associated with an increased risk of bradycardia, particularly in women, patients with poor CYP2D6 metabolism, and those with certain drug interactions. While the overall incidence is low, bradycardia can limit the ability to reach target doses and may necessitate careful monitoring, dose adjustment, or alternative therapies. Individual patient factors, including sex, genetic profile, and concurrent medications, should be considered to minimize the risk of bradycardia when prescribing metoprolol.
Sources and full results
Most relevant research papers on this topic